FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
HIV Infection

Interventions: Other: Laboratory Biomarker Analysis
Procedure: Leukapheresis

First Posted Date: 2009-08-31

Last Posted Date: 2017-05-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 9

Registration Number: NCT00968630

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Effects of Sulforaphane on Normal Prostate Tissue

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: High Sulforaphane Extract (Broccoli Sprout Extract)
Drug: Microcrystalline Cellulose NF (placebo)

First Posted Date: 2009-07-27

Last Posted Date: 2016-11-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 45

Registration Number: NCT00946309

Locations: 🇺🇸
VA Puget Sound, Seattle, Washington, United States

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Phase 1

Terminated

Conditions: Stage IV Melanoma
Stage III Melanoma
Recurrent Melanoma

Interventions: Biological: therapeutic autologous lymphocytes
Biological: aldesleukin
Biological: denileukin diftitox
Procedure: biopsy
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Genetic: polymerase chain reaction

First Posted Date: 2009-07-24

Last Posted Date: 2022-11-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00945269

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease

Phase 3

Completed

Conditions: Graft Versus Host Disease
Recurrent Adult Acute Lymphoblastic Leukemia

Interventions: Drug: prednisone
Drug: methylprednisolone
Other: questionnaire administration

First Posted Date: 2009-06-29

Last Posted Date: 2017-08-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 164

Registration Number: NCT00929695

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant

Completed

Conditions: Cardiovascular Complications
Leukemia
Long-term Effects Secondary to Cancer Therapy in Children
Metabolic Syndrome

First Posted Date: 2009-06-15

Last Posted Date: 2012-12-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 244

Registration Number: NCT00920842

Locations: 🇺🇸
Clinical Research Center - Seattle Children's Hospital, Seattle, Washington, United States

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Phase 2

Completed

Conditions: Non-Neoplastic Hematologic and Lymphocytic Disorder

Interventions: Biological: Anti-Thymocyte Globulin
Procedure: Allogeneic Bone Marrow Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation
Drug: Tacrolimus
Procedure: Umbilical Cord Blood Transplantation
Drug: Treosulfan

First Posted Date: 2009-06-12

Last Posted Date: 2021-08-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 98

Registration Number: NCT00919503

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

and more 3 locations

Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Stage II Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia
Stage I Small Lymphocytic Lymphoma
Stage III Small Lymphocytic Lymphoma
Stage IV Small Lymphocytic Lymphoma
Stage II Small Lymphocytic Lymphoma
Stage III Chronic Lymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Biological: Rituximab
Drug: Vorinostat

First Posted Date: 2009-06-11

Last Posted Date: 2020-02-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00918723

Locations: 🇺🇸
Swedish Cancer Institute-Breast Center at First Hill Campus, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Phase 2

Terminated

Conditions: Leukemia
Graft Versus Host Disease
Myelodysplastic Syndromes

Interventions: Drug: Fludarabine Phosphate
Drug: Tacrolimus
Drug: Thiotepa
Radiation: Total-Body Irradiation (TBI)
Other: Magnetic Affinity Cell Sorting
Procedure: Peripheral Blood Stem Cell Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation

First Posted Date: 2009-06-05

Last Posted Date: 2020-08-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 41

Registration Number: NCT00914940

Locations: 🇺🇸
Yale University School of Medicine/Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer

Completed

Conditions: Breast Cancer

First Posted Date: 2009-05-12

Last Posted Date: 2010-11-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1452

Registration Number: NCT00897416

MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

Not Applicable

Completed

Conditions: Hot Flashes
Menopause
Vasomotor Symptoms

Interventions: Other: Placebo
Drug: Escitalopram

First Posted Date: 2009-05-07

Last Posted Date: 2013-03-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 205

Registration Number: NCT00894543

Locations: 🇺🇸
Northern California Kaiser, Division of Research, Oakland, California, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy